Zobrazeno 1 - 10
of 270
pro vyhledávání: '"B. A. Sidorenko"'
Autor:
N. M. Savina, B. A. Sidorenko
Publikováno v:
Медицинский совет, Vol 0, Iss 4, Pp 10-15 (2016)
Primary and secondary prevention of cardiovascular complications (CVC) has been one of the key areas in modern cardiology over the past decades. The article examined the relationship between the risk of CVC and the lipid metabolism parameters. The ar
Externí odkaz:
https://doaj.org/article/42d540cbcdad4e0b921c5ae31666f44f
Publikováno v:
Кубанский научный медицинский вестник, Iss 5, Pp 109-113 (2015)
A total of 100 patients (86% - men, 14% are women), aged 56-69 years, which was later performed coronary artery bypass surgery. The methodology was based on a comprehensive survey assessing the functioning of the heart muscle, the clinical and instru
Externí odkaz:
https://doaj.org/article/f5ad0d20edc94d7a980b47ad16b94718
Autor:
D. V. Preobrazhensky, B. A. Sidorenko, S. A. Pataraya, T. A. Batyraliev, Z. A. Niyazova-Karben, Mesut Ishlek
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 6, Pp 69-79 (2009)
The review is devoted to modern pharmaceutical treatment of pulmonary arterial hypertension (PAH). In 1970-80s, it was based on high-dose calcium antagonists, CAs (e.g., nifedipine 240 mg/d), which were effective only in some patients with primary (i
Externí odkaz:
https://doaj.org/article/be849ca8d18d45629d9bfb4c7d225b54
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 7, Iss 6, Pp 79-88 (2008)
The review presents literature data on the key role of platelet aggregation (PA) for intracoronary thrombogenesis in various acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI). Clinical pharmacology of main antiplatelet medi
Externí odkaz:
https://doaj.org/article/eb3484a9051045bc9fc48cde0354b4f6
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 7, Iss 1, Pp 116-123 (2008)
Clinical pharmacology of ACE inhibitors is described, comparing pharmacological effects of agents with or without sulfhydryl groups in their molecules. Sulfhydryl group-containing ACE inhibitors – captopril and especially zofenopril – are charact
Externí odkaz:
https://doaj.org/article/6287b1f1cd99427b85e5e716224a4cec
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 1, Pp 87-94 (2006)
Externí odkaz:
https://doaj.org/article/f6330aefc1a145f6971a9c514a5b4c85
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 5, Pp 24-29 (2005)
Externí odkaz:
https://doaj.org/article/a8746cb2a0e543dbb483723ea0968034
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 4, Pp 5-13 (2004)
Externí odkaz:
https://doaj.org/article/d6654423d8ed471d8977fbfc59a291d8
Autor:
I. A. Sharoshina, B. A. Sidorenko, Y. V. Konev, N. E. Romanova, N. A. Ivanova, D. V. Preobrazhensky
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 6, Pp 89-95 (2003)
Clinical course, prognosis and therapy of chronic heart failure in patients with normal systolic and diastolic left ventricle function.
Externí odkaz:
https://doaj.org/article/537edce4ff094450909ac16cba23129a
Publikováno v:
Российский кардиологический журнал, Vol 0, Iss 3, Pp 81-86 (2003)
Role of natrium-uretic peptides in the diagnostics of heart failure.
Externí odkaz:
https://doaj.org/article/87a3cf69fa5a4814be6873414b7ad50c